OrganOx reported the completion of its acquisition by Terumo Corporation, following satisfaction of regulatory and closing conditions. OrganOx becomes a wholly owned subsidiary, with the combination intended to scale organ perfusion technologies and broaden global patient reach. The companies highlighted opportunities to invest in R&D, evolve the OrganOx metra platform beyond liver transplantation, and expand use of normothermic machine perfusion for organ support. OrganOx CEO Craig Marshall said joining Terumo will accelerate market expansion and operations to meet urgent demand for donor organs. OrganOx, spun out of the University of Oxford, notes its metra device is approved in multiple regions and has supported thousands of transplants.
Related articles
West Enclave Merger Corp. Announces the Separate Trading of its Ordinary Shares and Rights, Commencing May 13, 2026
May 8, 2026
Shreya Acquisition Group Announces Closing of $110 Million Initial Public Offering (Including Partial Exercise of Over-Allotment Option)
May 8, 2026
Con Edison Announces $2 Billion At-The-Market (ATM) Equity Offering Program
May 8, 2026
Generated by Yeal